Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Breast cancer, particularly hormone receptor-positive (HR+) and HER2-negative (HER2-) subtypes, stands as the predominant malignancy affecting young women globally, constituting roughly 30% of new cancer diagnoses and accounting for 25% of cancer-related deaths. The prognosis and clinical trajectory of metastatic breast cancer patients are highly variable, influenced by diverse factors, including patient characteristics such as age and existing health conditions, as well as tumor attributes like hormone receptor status, tumor grade, and site of metastasis. Although the median survival period for metastatic breast cancer is typically 2-4 years, specific subgroups may experience extended survival, particularly those with less aggressive or localized metastatic disease. Initial diagnosis reveals metastatic spread in about 6%-10% of cases. Despite advancements in treatment strategies for metastatic breast cancer, the impact on overall survival remains modest. Presently, metastatic breast cancer is largely deemed incurable, with treatment primarily aimed at palliation. Nevertheless, the emergence of novel therapeutic agents has spurred efforts to prolong survival in this setting. Treatment protocols vary depending on the molecular subtype of breast cancer. HER2-positive patients typically receive trastuzumab in combination with pertuzumab and a taxane in the first-line setting, while trastuzumab emtansine is preferred in the second line. Hormone receptor-positive and HER2-negative patients are typically treated with hormone therapy alone or in combination with a CDK inhibitor, such as palbociclib, in the first line, and subsequent lines may include hormone therapy with or without a CDK4/6 inhibitor, irrespective of BRCA status. For triple-negative breast cancer (TNBC) patients with PD-L1 expression, atezolizumab combined with nab-paclitaxel has rapidly gained acceptance as the standard first-line therapy following its approval in August 2019. Taxane-based regimens are commonly employed for TNBC patients lacking PD-L1 expression.

·       In the United States, an estimated 4.1 million women have a history of breast cancer, with approximately 4% of them living with metastatic disease. Alarmingly, over half of these individuals were initially diagnosed with early-stage (stages I-III) cancers.

 

Thelansis’s “Metastatic Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Metastatic Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Metastatic Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Metastatic Breast Cancer, Metastatic Breast Cancer market outlook, Metastatic Breast Cancer competitive landscape, Metastatic Breast Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)